286 related articles for article (PubMed ID: 20347511)
1. Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial.
Toussaint ND; Lau KK; Strauss BJ; Polkinghorne KR; Kerr PG
Am J Kidney Dis; 2010 Jul; 56(1):57-68. PubMed ID: 20347511
[TBL] [Abstract][Full Text] [Related]
2. Associations between vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease.
Toussaint ND; Lau KK; Strauss BJ; Polkinghorne KR; Kerr PG
Nephrol Dial Transplant; 2008 Feb; 23(2):586-93. PubMed ID: 17933842
[TBL] [Abstract][Full Text] [Related]
3. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
[TBL] [Abstract][Full Text] [Related]
4. Associations between vascular calcification, arterial stiffness and bone mineral density in chronic hemodialysis patients.
Aoki A; Kojima F; Uchida K; Tanaka Y; Nitta K
Geriatr Gerontol Int; 2009 Sep; 9(3):246-52. PubMed ID: 19702934
[TBL] [Abstract][Full Text] [Related]
5. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.
Ensrud KE; Barrett-Connor EL; Schwartz A; Santora AC; Bauer DC; Suryawanshi S; Feldstein A; Haskell WL; Hochberg MC; Torner JC; Lombardi A; Black DM;
J Bone Miner Res; 2004 Aug; 19(8):1259-69. PubMed ID: 15231012
[TBL] [Abstract][Full Text] [Related]
6. Effect of intradialytic versus home-based aerobic exercise training on physical function and vascular parameters in hemodialysis patients: a randomized pilot study.
Koh KP; Fassett RG; Sharman JE; Coombes JS; Williams AD
Am J Kidney Dis; 2010 Jan; 55(1):88-99. PubMed ID: 19932545
[TBL] [Abstract][Full Text] [Related]
7. Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial.
Perkins RM; Aboudara MC; Uy AL; Olson SW; Cushner HM; Yuan CM
Am J Kidney Dis; 2009 Apr; 53(4):606-16. PubMed ID: 19216016
[TBL] [Abstract][Full Text] [Related]
8. Association of carotid intima-medial thickness and indices of arterial stiffness with cardiovascular disease outcomes in CKD.
Zoungas S; Cameron JD; Kerr PG; Wolfe R; Muske C; McNeil JJ; McGrath BP
Am J Kidney Dis; 2007 Oct; 50(4):622-30. PubMed ID: 17900462
[TBL] [Abstract][Full Text] [Related]
9. [The effect of a one-year alendronate therapy on postmenopausal osteoporosis. (Results in Hungary of an international multicenter clinical study)].
Bettembuk P; Balogh A
Orv Hetil; 1999 Dec; 140(50):2799-803. PubMed ID: 10647267
[TBL] [Abstract][Full Text] [Related]
10. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
[TBL] [Abstract][Full Text] [Related]
11. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G
J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
[TBL] [Abstract][Full Text] [Related]
12. Markers of arterial stiffness are risk factors for progression to end-stage renal disease among patients with chronic kidney disease stages 4 and 5.
Taal MW; Sigrist MK; Fakis A; Fluck RJ; McIntyre CW
Nephron Clin Pract; 2007; 107(4):c177-81. PubMed ID: 17975325
[TBL] [Abstract][Full Text] [Related]
13. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
[TBL] [Abstract][Full Text] [Related]
14. Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease.
Sigrist MK; Taal MW; Bungay P; McIntyre CW
Clin J Am Soc Nephrol; 2007 Nov; 2(6):1241-8. PubMed ID: 17928470
[TBL] [Abstract][Full Text] [Related]
15. Stepwise increase in arterial stiffness corresponding with the stages of chronic kidney disease.
Wang MC; Tsai WC; Chen JY; Huang JJ
Am J Kidney Dis; 2005 Mar; 45(3):494-501. PubMed ID: 15754271
[TBL] [Abstract][Full Text] [Related]
16. Arterial calcification in patients with chronic kidney disease.
Koleganova N; Piecha G; Ritz E; Schirmacher P; Müller A; Meyer HP; Gross ML
Nephrol Dial Transplant; 2009 Aug; 24(8):2488-96. PubMed ID: 19329792
[TBL] [Abstract][Full Text] [Related]
17. Fetuin-A is an independent determinant of change of aortic stiffness over 1 year in non-diabetic patients with CKD stages 3 and 4.
Ford ML; Tomlinson LA; Smith ER; Rajkumar C; Holt SG
Nephrol Dial Transplant; 2010 Jun; 25(6):1853-8. PubMed ID: 20075438
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and associations of coronary artery calcification in patients with stages 3 to 5 CKD without cardiovascular disease.
Garland JS; Holden RM; Groome PA; Lam M; Nolan RL; Morton AR; Pickett W
Am J Kidney Dis; 2008 Nov; 52(5):849-58. PubMed ID: 18562059
[TBL] [Abstract][Full Text] [Related]
19. Aortic Calcification and Arterial Stiffness Burden in a Chronic Kidney Disease Cohort with High Cardiovascular Risk: Baseline Characteristics of the Impact of Phosphate Reduction On Vascular End-Points in Chronic Kidney Disease Trial.
Lioufas NM; Pedagogos E; Hawley CM; Pascoe EM; Elder GJ; Badve SV; Valks A; Toussaint ND;
Am J Nephrol; 2020; 51(3):201-215. PubMed ID: 32023606
[TBL] [Abstract][Full Text] [Related]
20. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
